Oncology Central

First-of-its-kind NSCLC vaccine moves into Phase I trial

0
A collaborative agreement between Cancer Research UK (UK) and Asterias Biotherapeutics Inc (CA, USA) has resulted in the first-of-its-kind vaccine moving into a Phase I clinical trial for patients with non-small cell lung cancer (NSCLC).

The vaccine, termed AST-VAC2 is derived from a standardised human embryonic stem cell line.

To view restricted content, please:
Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.